Wanjia Group Holdings (HKSE:00401) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00401 Wanjia Group Holdings Ltd HKSE:00401
35 GF Score
Price HK$0.13
GF Value HK$0.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Wanjia Group Holdings FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:00401
35GF Score
Wanjia Group Holdings Ltd HKSE:00401
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Wanjia Group Holdings (HKSE:00401) Overvalued in 2026?

Based on GuruFocus' analysis, Wanjia Group Holdings stock appears to be overvalued. The current stock price of HK$0.13 is trading 116.7% above its estimated GF Value™ of HK$0.06. GuruFocus considers Wanjia Group Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:00401:

  • FFO:
  • GF Value™: HK$0.06 vs. price of HK$0.13 (116.7% above fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the HKSE:00401 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wanjia Group Holdings Business Description

Address 25 Canton Road, Harbour City, Suite 1801, 18th Floor, Tower 1, The Gateway, Kowloon, Hong Kong, HKG
Wanjia Group Holdings Ltd is an investment holding company. Along with its subsidiaries, the company operates in principal activities of Pharmaceutical wholesale and distribution business, and Hemodialysis treatment and consultancy service business. The company generates key revenue from the Hemodialysis treatment and consultancy service business. Geographically, company operates in Hong Kong and China, having majority revenue generation from Mainland China.
35GF Score

Get the complete analysis for HKSE:00401

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.13
Price
HK$0.06
GF Value